New York City-based Hospital for Special Surgery is part of a multicenter trial examining the effectiveness of three disc replacement devices used for two-level symptomatic cervical disc disease.
The study, sponsored by Centinel Spine, will include patients ages 18 to 69 who have a diagnosis of radiculopathy or myelopathy with radiculopathy, according to a June 1 news release. About 390 patients will be enrolled in the trial.
Centinel Spine's Prodisc C and Prodisc C Vivo will be compared with Zimmer Biomet's Mobi C disc in the study.